In 2022, Behrouzi and colleagues published an updated meta-analysis of their previous study, examining published randomised clinical trials between 2000 and 2021. Studies that compared influenza vaccine vs placebo/control and included cardiovascular outcomes as endpoints were included. 
With the incorporation of the newer cardiovascular outcome trial results, they found that there was a 34% lower risk of composite cardiovascular events (3.6% of vaccinated patients developed a major cardiovascular event within 12 months versus 5.4% of those who received a placebo/control). The number needed to vaccinate was 56 to prevent one event. The risk reduction was even greater in those with a recent acute coronary syndrome.
Read the full paper on JAMA Network.